TIMER, R software and GEPIA2 were used to determine the difference in ANXA10 at the mRNA level, Fig. 1A shows that compared to normal adjacent tissues, expression of ANXA10 was significantly increased in lung squamous cell carcinoma (LUSC), prostate adenocarcinoma (PRAD), head and neck squamous cell carcinoma (HNSC), lung adenocarcinoma (LUAD) and thyroid carcinoma (THCA) but decreased in cholangiocarcinoma (CHOL) and liver hepatocellular carcinoma (LIHC). This evidence concerns the gene ANXA10 and thyroid gland carcinoma.